Research

MDA researchers first identified the genetic defect underlying spinal-bulbar muscular atrophy (SBMA) in the early 1990s. Since then, many MDA-supported research groups have worked to understand the disease and develop treatments for it.

Many MDA-supported projects are focused on understanding how the downstream effects of mutations in the androgen receptor gene affect cells, and developing methods to overcome or compensate for these effects.

Recently, some MDA researchers have been looking into the possibility of using a new class of drugs called selective androgen receptor modulators (SARMs) to treat SBMA.